Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab

Pediatric Blood and Cancer

Volumn 52, Issue 5, 2009, Pages 669-671

  Levy, Carolyn Fein ^a,c   Oo, Khine Zin ^a   Fireman, Fernando ^a   Pierre, Louisdon ^a   Bania, Marita A ^a   Sadanandan, Swayamprabha ^a   Yamashiro, Darrell J ^b   Bender, Julia L Glade ^b,d  

^a BROOKLYN HOSPITAL CENTER   (United States)

^b Surgeons of Columbia University ^*  (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^d Pediatric Oncology   (United States)

Author keywords

Bevacizumab; Hypertension; Reversible posterior leukoencephalopathy syndrome

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ENALAPRIL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LABETALOL; LOSARTAN; MINOXIDIL; NITROPRUSSIDE SODIUM; OXALIPLATIN; VINCRISTINE; MONOCLONAL ANTIBODY;

ANAMNESIS; ARTICLE; BLOOD PRESSURE REGULATION; CANCER SURGERY; CASE REPORT; CHILD; GENETIC ANALYSIS; HEPATOBLASTOMA; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; SEIZURE; BLOOD PRESSURE; CANCER STAGING; DRUG EFFECT; FATALITY; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PATHOPHYSIOLOGY;

ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; CHILD, PRESCHOOL; FATAL OUTCOME; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;

EID: 63649098308     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21866     Document Type: Article

References (16)

1. Glade Bender JL, Adamson PC, Reid JM, et al., Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: AChildren's Oncology Group Study. J Clin Oncol 2008;26:399-405.
2. Benesch M, Windelberg M, Sauseng W, et al., Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008;19:807-813.
3. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-1903.
4. Hinchey J, Chaves C, Appignani B, et al., A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
5. Ferraz-Filho JR, Rocha-Filho JA, Bichuette TF, et al., Studying the evolution and the magnetic resonance findings of reversible posterior leukoencephalopathy in children. Arq Neuropsiquiatr 2006;64:718-722.
6. Port JD, Beauchamp NJ Jr. Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radio- graphics 1998;18:353-367.
7. Sheth RD, Riggs JE, Bodenstenier JB, et al., Parietal occipital edema in hypertensive encephalopathy: A pathogenic mechanism. Eur Neurol 1996;36:25-28.
8. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475-1478.
9. Glusker P, Recht L, Lane B. Reversible posterior leukoencephal- opathy syndrome and bevacizumab. N Engl J Med 2006;354:980-982, discussion 980-982.
10. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalop- athy syndrome and bevacizumab. N Engl J Med 2006;354:980-982, discussion 980-982.
11. Iqbal K, Chu Q, Mei Q, et al., Bevacizumab-associated reversible hypotension. Clin Oncol (R Coll Radiol (Great Britain)) 2007; 19:800-801.
12. Pinedo DM, Shah-Khan F, Shah PC. Reversible Posterior Leukoencephalopathy Syndrome Associated With Oxaliplatin. J Clin Oncol 2007;25:5320-5321.
13. Burki F, Badie K, Bartoli P, et al., Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/ doxorubicin regimen. Br J Clin Pharmacol 2008;65:793-794.
14. El Maalouf G, Mitry E, Lacout A, et al., Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol 2008;255:295-296.
15. Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study. Rev Neurol 2008;164:588-594.
16. Koopman M, Muller EW, Punt CJ. Reversible Posterior Leukoen- cephalopathy Syndrome Caused by Bevacizumab: Report of a Case. Dis Colon Rectum 2008;51:1425-1426.